3月11日 - ** 生物技术公司Precision BioSciences DTIL.O股价盘前上涨1%至5.32美元
** 该公司称，美国专利商标局发布了加强PBGENE-HBV知识产权的通知，PBGENE-HBV是该公司针对慢性乙型肝炎（一种长期肝脏感染）的实验性基因编辑疗法。
** 称这些专利将涵盖其专有的基因编辑酶和一种可能用于未来疗法的新成分，预计保护期至少持续到 2044 年 11 月
** PBGENE-HBV 正在进行首次全球人体试验，目的是消除病毒在体内的存留形式--DTIL
** 公司称该项目已获得美国 FDA 快速通道资格
** 2025 年股价上涨约 9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.